HC Wainwright Weighs in on Absci’s Q1 Earnings (NASDAQ:ABSI)

Absci Corporation (NASDAQ:ABSI) – Analysts at HC Wainwright lowered their Q1 2026 earnings per share estimates for Absci in a research report issued to clients and investors on Wednesday, March 25th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.20) for the quarter, down from their previous estimate of ($0.13). HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Absci’s current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Absci’s Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at $0.10 EPS and FY2029 earnings at $0.08 EPS.

ABSI has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Absci in a report on Wednesday, January 21st. Morgan Stanley downgraded shares of Absci from an “overweight” rating to an “equal weight” rating and set a $4.32 price objective on the stock. in a research report on Thursday, January 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $7.00 target price on shares of Absci in a report on Wednesday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.08.

Absci Trading Down 3.5%

Shares of NASDAQ ABSI opened at $2.78 on Friday. The stock has a market cap of $425.40 million, a P/E ratio of -3.27 and a beta of 2.12. Absci has a twelve month low of $2.01 and a twelve month high of $5.23. The stock has a 50 day moving average of $2.76 and a two-hundred day moving average of $3.21.

Absci (NASDAQ:ABSI) last announced its earnings results on Tuesday, March 24th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.07). The firm had revenue of $0.65 million during the quarter, compared to analyst estimates of $1.38 million. Absci had a negative net margin of 4,113.68% and a negative return on equity of 62.33%.

Insiders Place Their Bets

In other news, CEO Sean Mcclain sold 26,761 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $2.99, for a total value of $80,015.39. Following the completion of the sale, the chief executive officer owned 8,334,567 shares in the company, valued at approximately $24,920,355.33. This trade represents a 0.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andreas Busch bought 100,000 shares of the stock in a transaction dated Thursday, March 12th. The stock was purchased at an average cost of $2.29 per share, for a total transaction of $229,000.00. Following the acquisition, the insider owned 421,446 shares of the company’s stock, valued at approximately $965,111.34. This represents a 31.11% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 10.49% of the company’s stock.

Institutional Investors Weigh In On Absci

A number of hedge funds have recently added to or reduced their stakes in ABSI. State Street Corp boosted its holdings in Absci by 190.1% in the 4th quarter. State Street Corp now owns 5,990,877 shares of the company’s stock valued at $20,908,000 after purchasing an additional 3,925,926 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of Absci during the 4th quarter worth approximately $8,201,000. Baker BROS. Advisors LP acquired a new stake in shares of Absci in the 4th quarter valued at approximately $7,450,000. ARK Investment Management LLC boosted its stake in shares of Absci by 21.1% in the third quarter. ARK Investment Management LLC now owns 12,162,773 shares of the company’s stock valued at $36,975,000 after buying an additional 2,116,845 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Absci by 2,955.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,156,067 shares of the company’s stock valued at $7,526,000 after buying an additional 2,085,501 shares in the last quarter. Institutional investors and hedge funds own 52.05% of the company’s stock.

Key Absci News

Here are the key news stories impacting Absci this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and an $8.00 price target and published an optimistic long‑term FY2030 EPS projection ($0.61), signaling conviction in Absci’s multi‑year growth story and providing upside support for the shares.
• Positive Sentiment: Needham & Company issued a Buy rating on Absci, giving additional independent analyst support that can help stabilize sentiment. Article Title
• Neutral Sentiment: Earnings call transcript coverage is available; the Q4 2025 call and accompanying commentary give detail on product programs and cash usage that investors should read to evaluate near‑term execution. MSN Transcript Yahoo Transcript
• Neutral Sentiment: Recent coverage flags Absci’s cash‑burn situation as a watch item — this is informational but its impact depends on runway, financing options and upcoming milestones. Cash Burn Article
• Negative Sentiment: HC Wainwright sharply reduced near‑term EPS estimates across multiple quarters and fiscal years (e.g., FY2026 EPS cut from about ($0.45) to ($0.87); Q1–Q4 2026 and FY2027–2029 estimates were also lowered). Those downgrades increase short‑term uncertainty and pressure the stock.
• Negative Sentiment: Seeking Alpha published a downgrade to “Hold,” citing a shift in clinical priorities (ABS‑101 deprioritized, pivot to ABS‑201) that raises execution risk and timeline uncertainty. That sell‑side/independent downgrading contributed to negative sentiment. Seeking Alpha
• Negative Sentiment: Pre‑market coverage noted Absci among stocks moving lower, reflecting intraday selling pressure following the analyst revisions and downgrade. Pre-market Article

Absci Company Profile

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.